[1] Lok AS,Zoulim F,Dusheiko G,et al. Hepatitis B cure: from discovery to regulatory approval.J Hepatol,2017,67: 847-861. [2] Kock J,Theilmann L,Galle P,et al.Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology,1996,23: 405-413. [3] Jansen L,Kootstra NA,Tanaka E,et al. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues. J Infect Dis,2016,213: 224-232. [4] U.S. Department of Health and Human, Services Food and Drug Administration. Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment; Guidance for Industry. The Federal Register/FIND,2018,83. [5] 中华肝脏病杂志, 临床肝胆病杂志, 《肝脏》杂志.HBV RNA病毒样颗粒的潜在临床意义[J]. 临床肝胆病杂志,2016,32: 1635-1636. [6] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67: 370-398. [7] Lu F,Wang J,Chen X,et al. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs. Front Med,2017, 11: 502-508. [8] Wang J,Shen T,Huang X,et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol,2016,65: 700-710. |